Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Su M, Page S, Haag M, Swisshelm K, Hennerich D, Graw S, et al. Clinical utility and cost-effectiveness analysis of chromosome testing concomitant with chromosomal microarray of patients with constitutional disorders in a U.S. academic medical center. J Genet Couns. 2022;31(2):364-374.

Berchuck JE, Adib E, Alaiwi SA, Dash AK, Shin JN, Lowder D, et al. The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response. Cancer Res. 2022;82(16):2848-2859.

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, et al. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022;35(4):470-479.

Lubetzky M, Zhao Z, Sukhu A, Sharma V, Sultan S, Kapur Z, et al. Characteristics of natural immunity to SARS-CoV-2 over time in wait-listed dialysis patients and recent kidney transplant recipients. Nephrol Dial Transplant. 2022;37(8):1585-1587.

Rodino KG, Peaper DR, Kelly BJ, Bushman F, Marques A, Adhikari H, et al. Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1. medRxiv. 2022.

Fowler FC, Chen B-, Zolnerowich N, Wu W, Pavani R, Paiano J, et al. DNA-PK promotes DNA end resection at DNA double strand breaks in G0 cells. Elife. 2022;11.

Greenberg J, Limberg J, Verma A, Kim D, Chen X, Lee YJ, et al. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. JCI Insight. 2022;7(23).

Kim S, Au CM, Bin Jamalruddin MA, Abou-Ghali NE, Mukhtar E, Portella L, et al. AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. Elife. 2022;11.

Nassar AH, Adib E, Alaiwi SA, Zarif TE, Groha S, Akl EW, et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022;40(10):1161-1172.e5.